Logo image of IBO

IMPACT BIOMEDICAL INC (IBO) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:IBO - US45259L2051 - Common Stock

0.4718 USD
-0.01 (-1.5%)
Last: 1/23/2026, 8:04:00 PM
0.47 USD
0 (-0.38%)
After Hours: 1/23/2026, 8:04:00 PM
Fundamental Rating

0

Overall IBO gets a fundamental rating of 0 out of 10. We evaluated IBO against 190 industry peers in the Pharmaceuticals industry. IBO may be in some trouble as it scores bad on both profitability and health. IBO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IBO has reported negative net income.
  • In the past year IBO has reported a negative cash flow from operations.
IBO Yearly Net Income VS EBIT VS OCF VS FCFIBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • The Return On Assets of IBO (-201.86%) is worse than 89.01% of its industry peers.
Industry RankSector Rank
ROA -201.86%
ROE N/A
ROIC N/A
ROA(3y)-48.88%
ROA(5y)N/A
ROE(3y)-207.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBO Yearly ROA, ROE, ROICIBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • IBO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBO Yearly Profit, Operating, Gross MarginsIBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for IBO remains at a similar level compared to 1 year ago.
  • IBO has a worse debt/assets ratio than last year.
IBO Yearly Shares OutstandingIBO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M 8M 10M
IBO Yearly Total Debt VS Total AssetsIBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • IBO has an Altman-Z score of -4.99. This is a bad value and indicates that IBO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -4.99, IBO is not doing good in the industry: 64.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.99
ROIC/WACCN/A
WACCN/A
IBO Yearly LT Debt VS Equity VS FCFIBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 0.06 indicates that IBO may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.06, IBO is doing worse than 96.86% of the companies in the same industry.
  • IBO has a Quick Ratio of 0.06. This is a bad value and indicates that IBO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.04, IBO is doing worse than 96.34% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.04
IBO Yearly Current Assets VS Current LiabilitesIBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

  • The earnings per share for IBO have decreased strongly by -509.26% in the last year.
EPS 1Y (TTM)-509.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1423.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IBO Yearly Revenue VS EstimatesIBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 10K 20K 30K 40K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IBO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBO Price Earnings VS Forward Price EarningsIBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBO Per share dataIBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • IBO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IMPACT BIOMEDICAL INC / IBO FAQ

What is the ChartMill fundamental rating of IMPACT BIOMEDICAL INC (IBO) stock?

ChartMill assigns a fundamental rating of 0 / 10 to IBO.


What is the valuation status for IBO stock?

ChartMill assigns a valuation rating of 0 / 10 to IMPACT BIOMEDICAL INC (IBO). This can be considered as Overvalued.


What is the profitability of IBO stock?

IMPACT BIOMEDICAL INC (IBO) has a profitability rating of 0 / 10.